CDK4 and cancer: Among all the CDK/cyclin complexes, aberrations resulting in hyperactivity of the CDK4/cyclin D complex are observed in numerous human cancers, with the most prevalent being breast carcinoma, melanoma, osteosarcoma, liposarcoma, glioblastoma, and neuroblastoma [44].